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ABSTRACT
p53 is a central factor in tumor suppression as exempliﬁed by its frequent loss in human cancer. p53 exerts its
tumor suppressive effects in multiple ways, but the ability to invoke the eradication of damaged cells by
programmed cell death is considered a key factor. The ways in which p53 promotes cell death can involve direct
activation or engagement of the cell death machinery, or can be via indirect mechanisms, for example though
regulation of ER stress and autophagy. We present here another level of control in p53-mediated tumor
suppression by showing that p53 activates the glycosidase, FUCA1, a modulator of N-linked glycosylation. We
show that p53 transcriptionally activates FUCA1 and that p53 modulates fucosidase activity via FUCA1 up-
regulation. Importantly, we also report that chemotherapeutic drugs induce FUCA1 and fucosidase activity in a
p53-dependent manner. In this context, while we found that over-expression of FUCA1 does not induce cell
death, RNAi-mediated knockdown of endogenous FUCA1 signiﬁcantly attenuates p53-dependent,
chemotherapy-induced apoptotic death. In summary, these ﬁndings add an additional component to p53s
tumor suppressive response and highlight another mechanism by which the tumor suppressor controls
programmed cell death that could potentially be exploited for cancer therapy.
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Introduction
The removal of damaged cells by programmed cell death is one of
the major mechanisms of tumor suppression.1 Cell death in this
context can be achieved by multiple mechanisms, but a key regula-
tor of this response is the tumor suppressor p53.2 The importance
of this protein in the prevention of tumor development is
highlighted by the fact that it is lost in approximately 50% of
humans cancers and that mice deﬁcient in p53 develop tumors by
6months of age3,4.While p53modulatesmultiple cellular pathways
that are important for tumor suppression, studies have shown that
its regulation of programmed cell death is of high importance.5
The protein primarily functions as a transcription factor and has
been shown to activate a spectrum of genes involved in cell death
regulation.6 These genes include a number that encode pro-apo-
ptotic members of the Bcl-2 family such as Puma and Noxa which
directly engage the intrinsic cell death pathway at mitochondria.7-9
In addition, p53 has also been reported to activate genes that stimu-
late the extrinsic apoptotic pathway.10 Moreover, in additional to
these transactivation-dependent mechanisms, p53 has also been
shown to regulate cell deathmore directly by binding to and repres-
sing anti-apoptotic members of the Bcl-2 family resulting in mito-
chondrial outer membrane permeabilisation (MOMP) and release
of apoptogenic factors into the cytosol.11-13
In addition to its role in tumor suppression, p53-induced pro-
grammed cell death is also an important factor in the response to
chemotherapy.14 Many chemotherapeutic drugs induce DNA-
damage which is a potent activation signal for p53.15-17 In unsti-
mulated cells, p53 is restrained by its target gene Mdm2 which
promotes p53 degradation. However, upon exposure to genotoxic
agents, this negative feedback loop is alleviated and the levels of
p53 increase and the protein becomes activated.16,17 The impor-
tance of this response in the effectiveness of chemotherapeutic
agents is reﬂected by the decreased cell death that is observed
upon drug exposure of p53-deﬁcient cells.14 Moreover, the fact
that cell death pathways can be perturbed during tumor develop-
ment - including those caused by loss of p53 - has important
implications for resistance to many chemotherapeutic drugs.
The perturbation of cell death pathways is only one facet of
tumor progression.1 For the development of cancer, cells must
attain a number of attributes which include for example, deregu-
lated proliferation, evasion of immune surveillance and immor-
tality.1 One characteristic on many cancers, however, that is
relatively under-investigated involves changes in glycosylation.
There are 2 principle forms of protein glycosylation and both
have been reported to be perturbed in human cancer.18 O-linked
glycosylation involves attachment of sugars to proteins via serine
or threonine, whereas N-linked glycosylation involves attachment
via asparagine.18 Interestingly, while increases and changes in
glycosylation are considered common events in human cancer,19
very few connections have been reported between the control of
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glycosylation and the signaling pathways that either promote or
repress tumor development. In this regard, we report here that
p53 can transcriptionally activate the gene encoding the glycosi-
dase FUCA1 which cleaves fucose linked moieties in N-linked
glycans. Moreover, we show that chemotherapeutic drugs acti-
vate FUCA1 via p53 and that FUCA1 is a contributing factor to
chemotherapy-induced cell death.
Materials and methods
Cell lines, cell culture and treatments
Saos2, RKO and U2OS cell lines were purchased from the Ameri-
can Type Culture Collection and maintained in DMEM (Gibco
BRL, Paisley, UK) containing 10% FBS, 4.5 g l¡1 glucose, 1 mML-
glutamine, 0.11 g l¡1 pyruvate andmaintained at 37C in 5% CO2
atmosphere. p53wt andmutant 273H inducible cell lines have been
previously described.20 Expression of p53 was induced using 1 mg/
ml of Doxycycline (Dox). RKO-LMP-Scr, RKO-LMP-p53, U2OS-
LMP-SCR, U2OS-LMP-p53 were generated by infection of RKO
and U2OS cells with LMP-Scr and LMP-p53 respectively.21 RKO-
pRS-Scr, RKO-pRS-p53, U2OS-pRS-SCR, U2OS-pRS-p53 were
previously described (Crighton 2006 and Crighton 2007). HCT116
p53¡/¡ cells were kind gift from Bert Vogelstein. E1a expressing
U2OS were previously described.22 TetOn-TAp73a Saos-2,
TetOn-TAp73b Saos-2, TetOn-TAp73g Saos-2 were kind gifts
from Gerry Melino and previously described.1 Expression of p73
was induced with 1mg/ml Dox.Where indicated, cells were treated
with Actinomycin D (ActD) (Sigma Aldrich St Louis, MI, USA);
Adriamycin, Cisplatin or etoposide (Calbiochem).
siRNA, plasmids and transfections
FUCA1 knockdown was performed using pre-designed on target
plus siRNAs purchased from Dharmacon (Lafayette, CO, USA).
siRNAs directed against FUCA1 were transfected using Oligo-
fectamine (Invitrogen, Life Technologies Paisley, UK) according
to the manufacturer’s instructions for 48 h before treatment.
pcDNA3-FUCAwt-Myc/His was generated by PCR and
cloned in to sites of pcDNA3.1MycHisA (Invitrogen, Life Tech-
nologies Paisley, UK). pcDNA3-FUCA1M1-Myc/His was gen-
erated by site-directed mutagenesis. pCMV-CD20 has been
previously described.23
Transient transfections into Saos2 cells were undertaken by
calcium phosphate precipitation using 5 mg of indicated plas-
mid together with 1mg pCMV-CD20.
qRT-PCR
qRT-PCR analysis was undertaken as previously described.22
FUCA1 and FUCA2 primers are QuantiTect primers from
QIAGEN. All samples were normalized to 18S rRNA and
expressed as relative mRNA expression.
Fuca1 enzymatic activity
The enzymatic activity of alpha-L-fucosidase was assessed as
previously described (Rapoport and Pendu 1999). Brieﬂy, cells
were lysed in 0.2 M acetate buffer pH5, containing 1% triton-X
100 (TTX), 0.1% SDS and protease inhibitor. Twenty-ﬁve mg of
protein in 100 ml of 0.2 M acetate buffer pH5 were incubated
in a 96 well plate together with 100 ml of 0.2mM 4-methylum-
belliferyl alpha-l-fucopyranoside (Sigma Aldrich St Louis, MI,
USA) for 90 minutes at 37C.
Western blotting
Cells were lysed in buffer containing 1% TTX, 0.1 % SDS,
50 mM HEPES pH 7.5, 150 mM NaCl, 100 mM NaF, 10 mM
EDTA, 10 mM Na4P2O7 and protease inhibitors (Roche) as
previously described.24 Protein concentrations were determined
by BCA assay (Sigma Aldrich St Louis, MI, USA). Cell lysates
were separated by SDS-PAGE and transfer into Immobilon-P
membranes (Millipore). Membranes were probed with anti-
p53, anti-p21 (sc-397, Santa Cruz, CA, USA), anti-HDM2,
anti-FUCA1, cleaved caspase-3, anti-PARP (Cell Signaling
Technology Beverly, MA, USA), Myc –tag (4A6) (Upstate
Biotechnology), b-actin (ab8227, Abcam, Cambridge, UK) or
Hsp90 (D-19) (Santa Cruz, CA, USA) antibodies.
Cell death analysis and caspase 3 activity
Cell death was evaluated by ﬂow cytometry (FACScalibur,
Becton Dickinson San Jose, CA, USA) as previously
described.25 The percentage of cells with sub-G1 DNA content
was taken as a measure of apoptotic rate.26
Cells which had been transfected with the pCMV-CD20 were
stained with a FITC-conjugated CD20 antibody, sorted for ﬂuores-
cence isothiocynate ﬂuorescence, and analyzed for DNA content.25
Clonogenic survival assays were performed on Saos2 cells
transfected with the indicated plasmids. 48 hours after transfec-
tion, cells were selected with 600 mg/ml G418 (Invitrogen, Life
Technologies Paisley, UK) for 2 to 3 weeks and then stained
with Giemsa (Sigma).
Caspase 3 activation was assessed by ﬂow cytometry. Cells
were ﬁxed and permeabilized with Cytoﬁx/Cytoperm, then
incubated for 30 min with anti-active caspase-3-FITC antibody.
Chromatin immunoprecipitation
Chromatin was prepared from Saos2 cells treated with or with-
out Dox. ChIP assays were performed using the ChIP-Assay kit
(Merck Millipore) according to manufacturer’s instructions.
Chromatin was immunoprecipitated with 10 mg of anti-human
p53 (clone DO-7, PharMingen) or anti-adenovirus E1A (Phar-
Mingen) as a negative control. PCR ampliﬁcations of FUCA1
region containing the consensus p53-binding sites, were per-
formed using the speciﬁc primers,
FUCA1 (i) GAGAACAAGGGTGCAAAAGG
TCGGTTTGCATAGTGGTCTTT
FUCA1 (ii) TGGGACTTCCTCAAATCTGC
TCATGTGGTTTTGCTGTCCACAG
Control primers have been previously described27. The amount
of coprecipitating DNA was normalized to inputs.
2300 A. D. BAUDOT ET AL.
Luciferase reporter assay
Saos-2 cells were co-transfected with luciferase reporter con-
structs containing potential p53 binding sites and either control
vector or a p53-WT-expressing construct. Twenty-four hours
post-transfection, cells were lysed in 200 ml of 1 £ Luciferase
Cell Culture Lysis Reagent (Promega, Southampton, UK) and
assayed for luciferase activity using the Veritas Microplate
Luminometer.
Luciferase constructs containing potential p53 binding site i:
AGGCTAGTCTCCAACTTGTGG within the promoter region
(chromosome 1: 23,868, 672) was generated by PCR using the
speciﬁc primer:
Forward(i): CTGGGATTACAGGCGCACCCCATG
Reverse(i): CCGGAGCCCGCATCGCTACCCTCAGCG
Luciferase constructs containing the potential p53 binding site
ii: GGGCAAGTTCATGCAAGTTC within intron 1 (chromo-
some 1: 23.865,667) was generated by PCR using the speciﬁed
primers
Forward(ii): TCGTTCCTACCAGAAGTGTTGAAG
Reverse(i): CCTGTGGACAGCAAAACCACATGAGC
Results
The glycosidase FUCA1 is a p53 target gene
As an approach to understand the mechanisms by which p53
directs programmed cell death, our group has previously per-
formed microarrays using p53-inducible cells to identify novel
p53 target genes. These microarray screens lead to the identiﬁ-
cation of DRAM1 and ADORA2B as genes activated by p53 in
response to cellular stress.22,28 With the aim of identifying other
factors regulated by p53 which contribute to its cell death
response, we once again scrutinized these microarray data.
Since little is known about the role of glycosylation in cancer,
we were drawn to the fact that the mRNA for the glycosidase
FUCA1 had increased levels when p53 was switched on in this
inducible system (array data not shown).
To examine the relationship between p53 and FUCA1 in
more detail, we performed qPCR on RNA from cells containing
a tetracycline-inducible (TetOn) transgene for either wild-type
p53 or a tumor-derived mutant of p53 in which amino acid 273
is changed from arginine to histidine. In conﬁrmation of our
microarray data we found that induction of wild-type p53 by
treatment with doxycycline (Dox) could induce FUCA1 as well
as 2 previously described target genes, HDM2 and p21 (Fig. 1A
and B).16,17,29 By contrast, the 273H mutant of p53 had no
impact on FUCA1 expression, nor did it affect p21 and HDM2
(Fig. 1A and B). Interestingly, p53 (either wild-type or mutant)
had no signiﬁcant impact on the expression of the FUCA1-
related gene, FUCA2 (Fig. S1A). Moreover, we also found that
FUCA1 was not induced by isoforms of the p53 family member
p73 (Fig. S1B), indicating that unlike many other genes induced
by p53, the induction of FUCA1 is to some level p53-speciﬁc.
We considered that FUCA1 may be a direct target gene of
p53 and so we examined the FUCA1 gene for p53 binding
sites using the previously described MH algorithm.30 This
revealed a number of potential p53 binding in the FUCA1
promoter and one potential site in FUCA1 Intron 1 (Fig. 1C).
Examination of these potential binding sites using chromatin
immuno-precipitations with a p53-speciﬁc antibody revealed
that p53 binds to the site within FUCA1 Intron 1 (shown as
site ii in Fig. 1C), whereas p53 binding could only be detected
at a low level at the cluster of potential binding sites identiﬁed
in the FUCA1 promoter (Fig. 1D). To test if the binding site
in FUCA1 Intron 1 is functionally signiﬁcant, we cloned this
site into a luciferase reporter construct. This construct was
then transiently transfected into p53-null Saos-2 cells either
with or without an expression construct for p53. As can be
seen in Figure 1E, expression of p53 caused an approximate
6-fold induction of this reporter construct, whereas p53 had
no effect on a reporter construct which contained the cluster
of potential p53 binding sites from the FUCA1 promoter
(Fig. 1E).
As our data indicated that FUCA1 was a direct p53 target gene,
we next examined if chemotherapeutic drugs which are known to
induce p53-dependent responses also lead to induction of FUCA1.
To test this we treated HCT116, U2OS and RKO cells, each of
which contain endogenous wild-type p53, with actinomycin D,
Adriamycin (doxorubicin) or etoposide. RNA was then isolated
from these cells and the levels of FUCA1 mRNA determined by
qPCR. This revealed that each of the chemotherapeutic agents
increased the levels of FUCA1 mRNA with varying degrees in the
cell types (Fig. 2A, C, E). Analysis of a p53-deﬁcient variant of
HCT116 cells,31 revealed that a large component of FUCA1 induc-
tion in response to Adriamycin and actinomycin D was p53-
dependent (Fig. 2A and B). In contrast, knockdown of p53 by
RNA interference in RKO cells revealed that induction of FUCA1
in these cells was also driven by p53, but only in response to
Adriamycin and etoposide (Fig. 2C and D). In U2OS cells, similar
to RKO cells, FUCA1mRNA levels were induced in a p53-depen-
dent manner in response to Adriamycin and etoposide (Fig. 2E
and F). In summary, we conclude that FUCA1 is a direct p53 tar-
get gene that is induced by several classes of chemotherapeutic
drugs. In many cases this effect involves a marked aspect of p53-
dependency, but clearly other factors are also involved the regula-
tion of FUCA1 in response to these drugs.
p53 and chemotherapeutic drugs induce
fucosidase activity
FUCA1 encodes for a glycosidase which cleaves fucose moieties
from N-linked glycan.32,33 As fucosidase activity is believed to
be central to FUCA1 function,34,35 we next sought to determine
if p53 could modulate fucosidase activity and whether this was
dependent on FUCA1. To this end, we adapted an in vitro
enzymatic assay using the ﬂuorogenic substrate 4-Methylum-
belliferyl-a-L-fucopyranoside (4-MU).36 4-MU has the prop-
erty to ﬂuoresce when it is excited at 365nm and this is directly
proportional to FUCA1activity. Examination of lysates from
TetOn-p53 cells that had been incubated in either the absence
or presence of Dox (to induce p53) revealed that expression of
p53 induces a gradual increase in fucosidase activity over time
that is coincident with an increase in FUCA1 protein levels
(Fig. 3A–B). To test if the increase in fucosidase activity
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induced by p53 is FUCA1-dependent, we induced p53 in
Saos-2 cells that had been transfected with 3 different FUCA1-
targeting siRNAs. In line with a role for endogenous FUCA1 in
this response, each of these siRNAs markedly impaired the abil-
ity of p53 to induce both FUCA1 levels and fucosidase activity
(Fig. 3C–D).
As we discovered that p53 can induce fucosidase activity, we
were interested to know if chemotherapeutic drugs can also
induce the activity of this enzyme. We therefore treated RKO
cells with either Adriamycin, cisplatin or etoposide for 48h
prior to examination of cell lysates for fucosidase activity using
our enzymatic assay. This indeed revealed that these 3 chemo-
therapeutic drugs induce fucosidase activity when administered
to cells (Fig. 3E–J). Moreover, using a matched cell line con-
taining a p53-targeting shRNA, we found that this increase in
fucosidase activity was virtually entirely p53 dependent
(Fig. 3E–J). We conclude therefore that fucosidase activity may
be important not only for the activity of p53 during tumor sup-
pression, but also for the therapeutic response of certain tumors
containing wild-type p53.
FUCA1 expression does not induce cell death, but FUCA1
is involved in p53’s apoptotic response
As the purpose of our microarray screens was to identify factors
involved in p53-mediated programmed cell death, we examined
if FUCA1 has a role in the regulation of cell viability. Firstly, we
over-expressed FUCA1 in Saos-2 cells which are known to
undergo a pronounced apoptotic response following expression
of p53. In line with previous reports, expression of p53 in these
Figure 1. FUCA1 is a direct p53 target gene. (A-B) TetOn-p53wt and TetOn-p53273H Saos2 cells were treated with doxycycline (Dox) for 24 hours. FUCA1 mRNA levels
were quantiﬁed by qRT-PCR and expressed as Relative Fuca1 mRNA level and represented as mean § SD (n D 2 independent experiments, 6 replicates, one way
Anova  p < 0.0001; n.s D non signiﬁcant)(A). p53, Hdm2 and p21expression were assessed by western blotting. Immunoblot against actin was used as a loading con-
trol (B). (C) Identiﬁcation of 2 potential p53 binding site in the sequence of FUCA1 gene: one in the promoter region (i) the other one in the ﬁrst intron (ii). (D) Chromatin
immunoprecipitation (ChIP) was performed on TetOn-p53 cells treated with Dox for 24 hr. Immunoprecipitations were carried out with anti-sera against p53 or a nonspe-
ciﬁc antibody (Ns). The % input of coprecipitating DNAs were calculated by quantitative PCR and presented as mean § SD (n D 3 independent experiements, one way
Anova: Site i pD 0.0053, Site iipD 0.0006, p21 p< 0.0001). (E) Saos-2 cells were co-transfected with either an empty pcDNA3 vector or a wild-type-p53-expressing
construct along with luciferase reporter constructs containing potential p53 binding sites i–ii (pGL3-FUCA1 i-ii) or vector control (pGL3 prom). Luciferase activity was ana-
lyzed 24 h after transfection and expressed as the relative fold increase relative to vector control (n D 4 independent experiements, one way Anova: Site i n.s p D 0.6751,
Site ii p < 0.0001).
2302 A. D. BAUDOT ET AL.
cells indeed caused a large proportion of cells to undergo apo-
ptosis as measured by analysis of cells with sub-G1 DNA con-
tent by ﬂow cytometry (Fig. 4A).26 By contrast, expression of
FUCA1 did not seem to affect apoptosis as measured by this
assay (Fig. 4A–B). Cell death was also not induced by a mutant
of FUCA1 that is associated with the lysosomal storage disor-
der, fucosidosis.37,38
Since FUCA1 overexpression does not appear to induce
apoptosis, we considered that FUCA1 may affect cell viability
by other mechanisms. To test this, we performed clonogenic
assays which act as readout for all events that can affect cell via-
bility or growth. As would be expected, expression of p53
signiﬁcantly affected the clonogenic potential of the cells
(Fig. 4C). Expression of FUCA1 however, appeared not to have
any impact in this assay with FUCA1-expressing cells having a
clonogenic potential equivalent to cells transfected with empty
plasmid (pcDNA3) as control (Fig. 4C).
Although over-expression of FUCA1 did not affect cell
viability, we considered that it may still have an effect on cell
death as a part of a p53 response in which other cell death
factors are induced or regulated. We therefore utilized FUCA1-
targeting siRNAs to knockdown FUCA1 in TetOn-p53 cells
and examined the effect this had on cell death following p53
induction. As can be seen in Figure 5A, each of the FUCA1-
Figure 2. FUCA1 is induced by gentoxic stress in a p53 dependent manner. (A-F) p53 null HCT116 (¡/¡p53) and WT HCT116 (C/Cp53) (A-B), RKO expressing scrambled
(LMP-Scr) or p53-speciﬁc (LMP-p53) shRNAs (C-D) and U2OS expressing scrambled (LMP-Scr) or p53-speciﬁc (LMP-p53) shRNAs (E-F) were treated with either Adriamycin
(Adr)(0.5 mg/ml), ActinomycinD (ActD)(2nM ) or Etoposide (Etop) (20 mm), for 24 hr prior to qRT-PCR quantiﬁcation of FUCA1 (A,C,E). Data are expressed as relative FUCA1
mRNA level and represented as mean § SD (n D 2 or 3 independent experiements, 5 to 9 replicates, one way Anova: p < 0.005 p < 0.001, p21 p < 0.0001). (B,D,F)
p53 expression were assessed by western blotting. Immunoblot against actin was used as a loading control.
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Figure 3. FUCA1 protein level and activity increase following p53 expression. (A-B) TetOn-p53wt Saos2 cells were treated with doxycycline (Dox) for 24 and 48 hours.
Fuca1 activity (A) was measured following Dox treatment and expressed as arbitrary units (A.U.) per 25 mg of protein (n D 3 independent experiement, 9 replicates, one
way Anova p < 0.0001). (B) FUCA1 and p53 expression was assessed by western blotting and immunoblot against actin was used as a loading control. (C-D) TetOn-
p53wt Saos2 cells were transfected with 3 different siRNA directed against FUCA1, prior to doxycycline treatment. Fuca1 enzymatic activities were assessed 48 hours after
p53 induction, expressed as arbitrary unit (A.U) per 25 mg of protein and represented as mean§ SD. The graph shown represnts data from one representative experiment
done with 3 technical replicates. p53 and Fuca1 expression were assessed by Western blotting and immunoblot against Hsp90 was used as a loading control. RKO
expressing scrambled (pRS-Scr) or p53-speciﬁc (pRS-p53) shRNAs were either Adriamycin (Adr)(0.5 mg/ml) (E-F), Cisplatin (Cis) (20 mM ) (G-H) or Etoposide (Etop)
(20 mm) (I-J) for 48 hr. FUCA1 activity was assessed and expressed as arbitrary units (A.U.) per 25 mg of protein (n D 3 independent experiement, 9 replicates, one way
Anova p D 0.0008, p < 0.0001). (E,G,I). FUCA1 and p53 expression was assessed by western blotting and immunoblot against actin was used as a loading control
(F,H,J).
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targeting siRNA reduced FUCA1 expression and also reduced
the percentage of cells with sub-G1 DNA content following
induction of p53 expression by treatment with Dox (Fig. 5A
and B). To conﬁrm if the effect on sub-G1 DNA content was
via modulation of p53-mediated apoptosis, we also examined
the effect of FUCA1 knockdown on the ability of p53 to
affected caspase activation and PARP cleavage – a substrate of
caspase activation.39 In both cases, it was clearly evident that
knockdown of FUCA1 impaired p53’s ability to increase the
activity of the effector caspase, caspase 3 and reduced the extent
of p53-induced PARP cleavage (Fig. 5C and D). These collec-
tive results therefore show that while FUCA1 does not affect
cell viability when expressed alone, it has a clear role in p53’s
apoptotic response.
Figure 4. FUCA1 overexpression is not sufﬁcient to induce cell death. Saos 2 cells were transiantly co-transfected with either an empty pcDNA3 vector, a wild-type-
Fuca1wt (pCDNA3 FUCA1wt), an enzymatically inactive mutant of FUCA1 (pCDNA3 FUCA1M1), or a wild-type-p53-expressing construct together with pCMV-CD20. After
72 h, the transfected cells were identiﬁed by staining for CD20 and analyzed for sub-G1 DNA content by ﬂow cytometry (n D 4 independent experiement, one way
Anova p < 0.0001) (A). (B) 24 hours post transfection p53 and Fuca1 expression were assessed by western blotting using respectively an anti-p53 antibody and an
anti-Myc-tag antibody. Immunoblot against actin was used as a loading control. (C) Saos-2 cells were transfected with either an empty pcDNA3 vector, a wild-type-
FUCA1wt (pCDNA3 FUCA1wt), an enzymatically inactive mutant of FUCA1 (pCDNA3 FUCA1M1), or a wild-type-p53-expressing construct. Following selection, cells were
assessed for clonogenic survival using Giemsa staining (C).
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Since we had discovered that FUCA1 and fucosidase activity
is induced by chemotherapeutic drugs in a p53-dependent man-
ner (Figs. 2A, B, and 3E–J), we were naturally intrigued to know
if FUCA1 plays a role in the apoptotic response to these agents.
To this end, we once again employed FUCA1-targeting siRNAs
to knockdown FUCA1 in RKO and U2OS cells. These cells were
then treated with either cisplatin (U2OS) or etoposide (U2OS
and RKO) and the levels of FUCA1 and apoptosis were assessed
by western blotting and ﬂow cytometry respectively (Fig. 5E–H
and Fig. S2). Following treatment with either drug, the extent of
Figure 5. FUCA1 expression contribute to Chemotherapeutic-induced cell death. (A-D). TetOn-p53wt Saos2 cells were were transfected with independent siRNA directed
against FUCA1 prior to doxycycline treatment (DOX) for 48 hours. (A) P53 and Fuca1 expression were assessed by Western blotting and immunoblot against Hsp90 was
used as a loading control. Cell death was analyzed by ﬂow cytometry, measuring the percentage of cells with sub-G1 DNA content (n D 3 independent experiement, one
way Anova p < 0.01,p < 0.0001) (B), Caspase 3 activation using an anti-active caspase 3 antibody (C), and western blotting assessing PARP cleavage (D). (E-H) U2OS
E1a were trasfected with 2 different siRNA directed against FUCA1 prior treatment with 20 mM Cisplatin (Cis) (E-F) or 20 mM Etoposide (Etop) (G-H) for 48 hours. Cells
were assessed for cell death by ﬂow cytometry measuring sub-G1 DNA content content (n D 2 independent experiement, 6 replicates one way Anova,p < 0.0001)
(E-G) and expression of Fuca1 by western blotting. Actin was used as a loading control (F-H).
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FUCA1 induction was greatly reduced in cells transfected with
FUCA1-targeting siRNAs when compared to controls (Fig. 5F,
H and Fig. S2B). In addition and in line with a role for FUCA1
in p53-mediated cell death, the extent of apoptosis induced by
etoposide or cisplatin was also markedly reduced by knockdown
of FUCA1 (Fig. 5E, 5G and Fig. S2A).
Discussion
In this studywe report that the gene encoding the fucosidase FUCA1
is induced by the tumor suppressor p53.We show that p53mediates
this effect by direct transcriptional activation through binding of p53
to FUCA1 at a site within intron 1 of the gene. Moreover, we also
report that FUCA1 is induced by different classes of chemotherapeu-
tic drugs in a p53-dependentmanner indicating that the induction of
FUCA1 is a function of endogenous p53. Interestingly, for a gene
that is so widely induced by p53, we were surprised to ﬁnd that
FUCA1 is not induced by the p53 family member, p73. In contrast,
many key components of p53-mediated tumor suppression includ-
ing p21 and PUMA have also been reported to be induced by p73.40-
42 So, what does this tell us about the selective activation of FUCA1
by p53? It could be considered that FUCA1 is a relatively ‘weak’ tar-
get gene that is only moderately induced by p53 and as a result not
induced by other p53-related proteins. Comparison, however, of the
levels of FUCA1 and other p53 targets studied in this TetOn system
or in response to chemotherapeutic drugs, such as DRAM1 and
ADORA2B, which are also induced by p73,43,44 shows that the induc-
tion of FUCA1 by p53 is at least equivalent. So, does this tell us that
the function of p53 is indeed something speciﬁc to p53? Since p53
has a greater impact on tumor suppression compared to p73, it is
tempting to speculate that the regulation of FUCA1 represents a
component of this p53-speciﬁc effect and future studies in this area
would certainly be worthwhile.
Although beyond the scope of the present study, another
question arising from our ﬁndings relates to how FUCA1 con-
tributes to p53-mediated apoptotic death. Intriguingly, we found
that expression of FUCA1 alone does not induce cell death indi-
cating that unlike the induction of pro-apoptotic members of the
Bcl2 family e.g. PUMA, NOXA and Bax,7-9,45 FUCA1 does not
contribute to cell death via direct engagement of the cell death
machinery. It is therefore clear that p53 must induce other target
genes that work in conjunction with FUCA1 in order to execute
a cell death response. It seems likely though that this would not
be one target gene, but a number of other p53 targets making
their identiﬁcation a considerable challenge. As a result, perhaps
future studies should focus on what functions of FUCA1 contrib-
ute to this effect. In this regard, we also report in this study that
p53 and chemotherapeutic drugs not only induce FUCA1, but
they also induce fucosidase activity. When this is coupled with
the fact that naturally occurring mutations in FUCA1 that lead
to fucosidosis all involve impairment of fucosidase activity,37,38 it
seems conceivable that FUCA1 also contributes to p53-induced
cell death through this enzymatic activity. If this is the case, then
FUCA1 would function by the removal of fucose moieties from
selective target proteins. As a result, the levels or activities of
these proteins would change in a way that together with the
action of other p53 target genes would push cells toward elimi-
nation by apoptotic death. Currently, however, no substrates of
fucosidase activity have been identiﬁed making this a large area
for further investigation.
Since p53 and programmed cell death are both important
components of tumor suppression, perhaps the biggest ques-
tion arising from this work regards the role of fucosylation con-
trol in cancer. Interestingly, several previous studies have
reported that glycosylation and more speciﬁcally fucosylation
are perturbed during tumor development.18 Moreover,
increased levels of a fucosylated protein are even used as an
FDA-approved biomarker for the detection of hepatocellular
carcinoma.46,47 However, whether these changes in glycosyla-
tion actually contribute to tumor development is still an open
question. The evidence we provide in this study undoubtedly
adds weight to this possibility, but the ﬁeld is currently lacking
appropriate animal models with which to address this issue.
The development of mice where FUCA1 and as a result fucosi-
dase activity could be deleted during the genesis of cancer as
would be a great step forward in this area. In addition, since we
show that FUCA1 and fucosidase activity are induced by che-
motherapeutic drugs, the development of mice in which the rel-
ative levels of fucosylation could be modulated in established
tumors may well lead to the identiﬁcation of novel targets for
treatment of tumors associated with changes in glycosylation.
Disclosure of potential conﬂicts of interest
The authors do not have any ﬁnancial, personal or professional interests to
declare that could be construed to inﬂuence this paper.
Acknowledgments
We would like to thank Scott Lowe for providing RNAi constructs to target
p53 and Bert Vogelstein for providing p53¡/¡ HCT116 cells.
Funding
This work was supported by Worldwide Cancer Research and Cancer
Research UK.
References
[1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.
cell.2011.02.013
[2] Vogelstein B, Lane D, Levine AJ. Surﬁng the p53 network. Nature
2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675
[3] Beroud C, Soussi T. The UMD-p53 database: new mutations and
analysis tools. Human mutation 2003; 21:176-81; PMID:12619103;
http://dx.doi.org/10.1002/humu.10187
[4] Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery
CA, Jr., Butel JS, Bradley A. Mice deﬁcient for p53 are developmen-
tally normal but susceptible to spontaneous tumours. Nature 1992;
356:215-21; PMID:1552940; http://dx.doi.org/10.1038/356215a0
[5] Attardi LD. The role of p53-mediated apoptosis as a crucial anti-
tumor response to genomic instability: lessons from mouse models.
Mutat Res 2005; 569:145-57; PMID:15603759; http://dx.doi.org/
10.1016/j.mrfmmm.2004.04.019
[6] Bieging KT, Attardi LD. Deconstructing p53 transcriptional net-
works in tumor suppression. Trends Cell Biol 2012; 22:97-106;
PMID:22154076; http://dx.doi.org/10.1016/j.tcb.2011.10.006
[7] Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is
induced by p53. Mol Cell 2001; 7:683-94; PMID:11463392; http://dx.
doi.org/10.1016/S1097-2765(01)00214-3
CELL CYCLE 2307
[8] Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces
the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7:673-82;
PMID:11463391; http://dx.doi.org/10.1016/S1097-2765(01)00213-1
[9] Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T,
Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the
Bcl-2 family and candidate mediator of p53-induced apoptosis. Sci-
ence 2000; 288:1053-8; PMID:10807576; http://dx.doi.org/10.1126/
science.288.5468.1053
[10] Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fuji-
wara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, et al. Wild-
type human p53 and a temperature-sensitive mutant induce Fas/
APO-1 expression. Mol Cell Biol 1995; 15:3032-40; PMID:7539102;
http://dx.doi.org/10.1128/MCB.15.6.3032
[11] Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer
DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates
mitochondrial membrane permeabilization and apoptosis. Science
2004; 303:1010-4; PMID:14963330; http://dx.doi.org/10.1126/
science.1092734
[12] Leu JI, Dumont P, HafeyM,MurphyME, George DL.Mitochondrial p53
activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol
2004; 6:443-50; PMID:15077116; http://dx.doi.org/10.1038/ncb1123
[13] Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P,
Moll UM. p53 has a direct apoptogenic role at the mitochondria.
Mol Cell 2003; 11:577-90; PMID:12667443; http://dx.doi.org/
10.1016/S1097-2765(03)00050-9
[14] Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis
modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67;
PMID:8402885; http://dx.doi.org/10.1016/0092-8674(93)90719-7
[15] Crighton D, Ryan KM. Splicing DNA-damage responses to tumour
cell death. Biochim Biophys Acta 2004; 1705:3-15; PMID:15585169
[16] Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by
Mdm2. Nature 1997; 387:299-303; PMID:9153396; http://dx.doi.org/
10.1038/387299a0
[17] Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid deg-
radation of p53. Nature 1997; 387:296-9; PMID:9153395; http://dx.
doi.org/10.1038/387296a0
[18] Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical
implications. Nat Rev Cancer 2015; 15:540-55; PMID:26289314;
http://dx.doi.org/10.1038/nrc3982
[19] Varki A, Kannagi R, Toole BP. Glycosylation Changes in Cancer. In:
Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi
CR, Hart GW, Etzler ME, eds. Essentials of Glycobiology. Cold
Spring Harbor (NY): Cold Spring Harbor Laboratory Press. The
Consortium of Glycobiology Editors, La Jolla, California, 2009.
[20] Ryan KM, O’Prey J, Vousden KH. Loss of nuclear factor-kappaB is
tumor promoting but does not substitute for loss of p53. Cancer Res
2004; 64:4415-8.
[21] Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ,
Lowe SW. Probing tumor phenotypes using stable and regulated synthetic
microRNA precursors. Nat Genet 2005; 37:1289-95; PMID:16200064
[22] Long JS, Crighton D, O’Prey J, Mackay G, Zheng L, Palmer TM, Gottlieb
E, Ryan KM. Extracellular adenosine sensing-a metabolic cell death
priming mechanism downstream of p53. Molecular Cell 2013; 50:394-
406; PMID:23603120; http://dx.doi.org/10.1016/j.molcel.2013.03.016
[23] Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D,
Dyson N, Harlow E. Inhibition of cell proliferation by p107, a relative
of the retinoblastoma protein. Genes Dev 1993; 7:1111-25;
PMID:8319904; http://dx.doi.org/10.1101/gad.7.7a.1111
[24] Baudot AD, Haller M,MrschtikM, Tait SW, Ryan KM. Using enhanced-
mitophagy to measure autophagic ﬂux. Methods 2015; 75:105-11;
PMID:25498004; http://dx.doi.org/10.1016/j.ymeth.2014.11.014
[25] Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in
p53-mediated programmed cell death. Nature 2000; 404:892-7;
PMID:10786798; http://dx.doi.org/10.1038/35009130
[26] Pellicciari C, Manfredi AA, Bottone MG, Schaack V, Barni S. A single-
step staining procedure for the detection and sorting of unﬁxed apo-
ptotic thymocytes. Eur J Histochem 1993; 37:381-90; PMID:7510545
[27] Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H.
p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 2003;
5:216-23; PMID:12598906; http://dx.doi.org/10.1038/ncb943
[28] Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR,
Gasco M, Garrone O, Crook T, Ryan KM. DRAM, a p53-induced
modulator of autophagy, is critical for apoptosis. Cell 2006; 126:121-
34; PMID:16839881; http://dx.doi.org/10.1016/j.cell.2006.05.034
[29] el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent
JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential
mediator of p53 tumor suppression. Cell 1993; 75:817-25;
PMID:8242752; http://dx.doi.org/10.1016/0092-8674(93)90500-P
[30] Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. The p53MH
algorithm and its application in detecting p53-responsive genes. Proc
Natl Acad Sci U S A 2002; 99:8467-72; PMID:12077306; http://dx.
doi.org/10.1073/pnas.132268899
[31] Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP,
Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21
to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501;
PMID:9822382; http://dx.doi.org/10.1126/science.282.5393.1497
[32] Johnson SW, Alhadeff JA. Mammalian alpha-L-fucosidases. Comp
Biochem Physiol B 1991; 99:479-88; PMID:1769200; http://dx.doi.
org/10.1016/0305-0491(91)90327-A
[33] Tsay GC, Dawson G, Sung SS. Structure of the accumulating oligosac-
charide in fucosidosis. J Biol Chem 1976; 251:5852-9; PMID:972144
[34] Winchester B. Lysosomal metabolism of glycoproteins. Glycobiology
2005; 15:1r-15r; PMID:15647514; http://dx.doi.org/10.1093/glycob/
cwi041
[35] Yamashita K, Tachibana Y, Takada S, Matsuda I, Arashima S, Kobata
A. Urinary glycopeptides of fucosidosis. J Biol Chem 1979; 254:4820-
7; PMID:438217
[36] Rapoport E, Pendu JL. Glycosylation alterations of cells in late phase
apoptosis from colon carcinomas. Glycobiology 1999; 9:1337-45;
PMID:10561459; http://dx.doi.org/10.1093/glycob/9.12.1337
[37] Willems PJ, Gatti R, Darby JK, Romeo G, Durand P, Dumon JE,
O’Brien JS. Fucosidosis revisited: a review of 77 patients. Am J Med
Genet 1991; 38:111-31; PMID:2012122; http://dx.doi.org/10.1002/
ajmg.1320380125
[38] Willems PJ, Seo HC, Coucke P, Tonlorenzi R, O’Brien JS. Spectrum
of mutations in fucosidosis. Eur J Hum Genet 1999; 7:60-7;
PMID:10094192; http://dx.doi.org/10.1038/sj.ejhg.5200272
[39] Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw
WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with
properties like ICE. Nature 1994; 371:346-7; PMID:8090205; http://
dx.doi.org/10.1038/371346a0
[40] Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M,
Knight RA, Green DR, Thompson C, Vousden KH. p73 Induces apo-
ptosis via PUMA transactivation and Bax mitochondrial transloca-
tion. J Biol Chem 2004; 279:8076-83; PMID:14634023; http://dx.doi.
org/10.1074/jbc.M307469200
[41] Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A,
Minty A, Chalon P, Lelias JM, Dumont X, et al. Monoallelically
expressed gene related to p53 at 1p36, a region frequently deleted in
neuroblastoma and other human cancers. Cell 1997; 90:809-19;
PMID:9288759; http://dx.doi.org/10.1016/S0092-8674(00)80540-1
[42] Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of
human] p53-related protein that can induce apoptosis. Nature 1997;
389:191-4; PMID:9296498; http://dx.doi.org/10.1038/38298
[43] Crighton D, O’Prey J, Bell HS, Ryan KM. p73 regulates DRAM-inde-
pendent autophagy that does not contribute to programmed cell
death. Cell Death Differ 2007; 14:1071-9; PMID:17304243; http://dx.
doi.org/10.1038/sj.cdd.4402108
[44] Long JS, Schoonen PM, Graczyk D, O’Prey J, Ryan KM. p73 engages
A2B receptor signalling to prime cancer cells to chemotherapy-
induced death. Oncogene 2015; 34:5152-62; PMID:25659586; http://
dx.doi.org/10.1038/onc.2014.436
[45] Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcrip-
tional activator of the human bax gene. Cell 1995; 80:293-9;
PMID:7834749; http://dx.doi.org/10.1016/0092-8674(95)90513-8
[46] Mehta A, Block TM. Fucosylated glycoproteins as markers of liver
disease. Dis Markers 2008; 25:259-65; PMID:19126969; http://dx.doi.
org/10.1155/2008/264594
[47] Warnes TW, Smith A. Tumour markers in diagnosis and manage-
ment. Bailliere’s Clin Gastroenterol 1987; 1:63-89; PMID:2437983
2308 A. D. BAUDOT ET AL.
